石雪英 赵金

    [摘要] 胰腺癌是目前恶性程度极高的肿瘤之一，因其发病隐匿，多数患者确诊时已发展为晚期，失去手术机会，因此，化疗成为晚期胰腺癌主要治疗措施。吉西他滨以其作用机制独特，毒性反应低，与其他化疗药物联合使用无交叉耐药等优点成为胰腺癌一线化疗药物。由于吉西他滨单药疗效有限，且存在大剂量使用出现毒副作用和耐药性等问题，国内外学者不断探索吉西他滨联合用药以及吉西他滨纳米载体药物递送等技术，以提高胰腺癌患者的生存期和生存质量。

    [关键词] 吉西他滨;胰腺癌;联合化疗

    [中图分类号] R453? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-7210(2020)07(c)-0050-04

    Research progress of Gemcitabine in combined therapy of pancreatic cancer

    SHI Xueying? ?ZHAO Jin

    Department of General Surgery， Baogang Hospital of Inner Mongolia， Inner Mongolia Autonomous Region， Baotou? ?014010， China

    [Abstract] Pancreatic cancer is one of the most aggressive tumors at present. Because of its occult incidence， most patients have been diagnosed as advanced stage and lost the opportunity of operation. Therefore， chemotherapy has become the main treatment for advanced pancreatic cancer. Gemcitabine has become the first-line chemotherapy drug for pancreatic cancer because of its unique mechanism ......